JP2021514400A - Egfrの阻害剤およびその使用法 - Google Patents

Egfrの阻害剤およびその使用法 Download PDF

Info

Publication number
JP2021514400A
JP2021514400A JP2020566548A JP2020566548A JP2021514400A JP 2021514400 A JP2021514400 A JP 2021514400A JP 2020566548 A JP2020566548 A JP 2020566548A JP 2020566548 A JP2020566548 A JP 2020566548A JP 2021514400 A JP2021514400 A JP 2021514400A
Authority
JP
Japan
Prior art keywords
carbon atoms
egfr
formula
optionally substituted
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020566548A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021514400A5 (cg-RX-API-DMAC7.html
Inventor
ナサニエル・エス・グレイ
ドリス・ド・クレルク
ジェボン・ジャン
パシ・ジャンヌ
チリッチ・ト
マイケル・エク
ウンヨン・パク
デイヴィッド・ヘップナー
Original Assignee
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド, デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド filed Critical デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド
Publication of JP2021514400A publication Critical patent/JP2021514400A/ja
Publication of JP2021514400A5 publication Critical patent/JP2021514400A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2020566548A 2018-02-20 2019-02-20 Egfrの阻害剤およびその使用法 Pending JP2021514400A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862632819P 2018-02-20 2018-02-20
US62/632,819 2018-02-20
US201862744086P 2018-10-10 2018-10-10
US62/744,086 2018-10-10
PCT/US2019/018773 WO2019164948A1 (en) 2018-02-20 2019-02-20 Inhibitors of egfr and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2021514400A true JP2021514400A (ja) 2021-06-10
JP2021514400A5 JP2021514400A5 (cg-RX-API-DMAC7.html) 2022-02-25

Family

ID=67687390

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020566548A Pending JP2021514400A (ja) 2018-02-20 2019-02-20 Egfrの阻害剤およびその使用法

Country Status (6)

Country Link
US (1) US20200390783A1 (cg-RX-API-DMAC7.html)
EP (1) EP3755690A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021514400A (cg-RX-API-DMAC7.html)
AU (1) AU2019225806A1 (cg-RX-API-DMAC7.html)
CA (1) CA3087288A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019164948A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021514399A (ja) * 2018-02-20 2021-06-10 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Egfrの阻害剤およびその使用法

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119317636A (zh) * 2023-03-07 2025-01-14 艾博生物科技(上海)有限公司 编码活化EGFR突变肽的免疫调节治疗性mRNA组合物
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040254159A1 (en) * 2003-02-27 2004-12-16 Hasvold Lisa A. Heterocyclic kinase inhibitors
WO2006061126A2 (en) * 2004-12-09 2006-06-15 F. Hoffmann-La Roche Ag Dibenzoxazepinone derivatives
US20070105835A1 (en) * 2005-11-07 2007-05-10 Kazantsev Aleksey G Compositions and methods for modulating poly(ADP-ribose) polymerase activity
WO2009124399A1 (en) * 2008-04-11 2009-10-15 Thallion Pharmaceuticals Inc. Inhibition of cell migration by a farnesylated dibenzodiazepinone
WO2012045194A1 (en) * 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazepinones as fak inhibitors for treatment of cancer
JP2012511054A (ja) * 2008-12-08 2012-05-17 ブイエム ファーマ エルエルシー タンパク質受容体チロシンキナーゼ阻害薬の組成物
WO2014160430A1 (en) * 2013-03-13 2014-10-02 Georgetown University Small molecule lrrk2 and erk5 inhibitors
JP2015205911A (ja) * 2009-01-06 2015-11-19 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド ピリミド−ジアゼピノンキナーゼ骨格化合物及び疾患を治療する方法
WO2015196072A2 (en) * 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
WO2017024317A2 (en) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017177092A1 (en) * 2016-04-07 2017-10-12 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating pi3k-mediated disorders
WO2017185023A1 (en) * 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 9 (cdk9) by conjugation of cdk9 inhibitors with e3 ligase ligand and methods of use
JP2021514399A (ja) * 2018-02-20 2021-06-10 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Egfrの阻害剤およびその使用法

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040254159A1 (en) * 2003-02-27 2004-12-16 Hasvold Lisa A. Heterocyclic kinase inhibitors
WO2006061126A2 (en) * 2004-12-09 2006-06-15 F. Hoffmann-La Roche Ag Dibenzoxazepinone derivatives
US20070105835A1 (en) * 2005-11-07 2007-05-10 Kazantsev Aleksey G Compositions and methods for modulating poly(ADP-ribose) polymerase activity
WO2009124399A1 (en) * 2008-04-11 2009-10-15 Thallion Pharmaceuticals Inc. Inhibition of cell migration by a farnesylated dibenzodiazepinone
JP2012511054A (ja) * 2008-12-08 2012-05-17 ブイエム ファーマ エルエルシー タンパク質受容体チロシンキナーゼ阻害薬の組成物
JP2015205911A (ja) * 2009-01-06 2015-11-19 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド ピリミド−ジアゼピノンキナーゼ骨格化合物及び疾患を治療する方法
WO2012045194A1 (en) * 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazepinones as fak inhibitors for treatment of cancer
WO2014160430A1 (en) * 2013-03-13 2014-10-02 Georgetown University Small molecule lrrk2 and erk5 inhibitors
WO2015196072A2 (en) * 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
WO2017024317A2 (en) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017177092A1 (en) * 2016-04-07 2017-10-12 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating pi3k-mediated disorders
WO2017185023A1 (en) * 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 9 (cdk9) by conjugation of cdk9 inhibitors with e3 ligase ligand and methods of use
JP2021514399A (ja) * 2018-02-20 2021-06-10 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Egfrの阻害剤およびその使用法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MASTALERZ, HAROLD ET AL.: "Novel C-5 aminomethyl pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. (2007), 17(10), 2828-2833, JPN6023003317, 2007, ISSN: 0004975939 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021514399A (ja) * 2018-02-20 2021-06-10 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Egfrの阻害剤およびその使用法
JP7335275B2 (ja) 2018-02-20 2023-08-29 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Egfrの阻害剤およびその使用法

Also Published As

Publication number Publication date
US20200390783A1 (en) 2020-12-17
WO2019164948A1 (en) 2019-08-29
AU2019225806A1 (en) 2020-07-16
CA3087288A1 (en) 2019-08-29
EP3755690A1 (en) 2020-12-30
EP3755690A4 (en) 2021-10-27

Similar Documents

Publication Publication Date Title
JP6845165B2 (ja) Egfr阻害剤およびその使用方法
JP6968823B2 (ja) Egfrの分解のための二官能性分子、及び使用方法
JP2021514011A (ja) Egfr阻害剤の組合せ医薬製剤およびその使用法
TW202340209A (zh) 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
US20200390783A1 (en) Inhibitors of egfr and methods of use thereof
AU2014309788B2 (en) Novel quinoline-substituted compound
CN110546145B (zh) 一种氮杂芳基衍生物、其制备方法和在药学上的应用
JP2021512059A (ja) ブルトン型チロシンキナーゼ(btk)阻害剤のe3リガーゼリガンドとのコンジュゲーションによるbtkの分解および使用方法
JP7335275B2 (ja) Egfrの阻害剤およびその使用法
JP2021514012A (ja) Egfrの分解誘導剤およびその使用法
JP2021514398A (ja) Egfr阻害剤の組合せ医薬製剤およびその使用法
US20200377477A1 (en) Degraders of egfr and methods of use thereof
JP2021514397A (ja) Egfr阻害剤の組合せ医薬製剤およびその使用法
HK40003735B (en) Bifunctional molecules for degradation of egfr and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220216

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230904